Innovotech Inc. (TSX Venture Exchange:IOT; OTCQB:IOTCF) announced today that its subsidiary, Innovotech Labs Corporation, is receiving advisory services and research and development funding of up to $234,000 CAD from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The funding will support the development of new antimicrobial testing services for medical devices such as catheters, implants, and wound dressings.
The new testing methods align with changes in international regulatory standards and medical device manufacturers’ needs in the areas of proliferation, biofilm formation, and translocation of microorganisms. This work builds on foundational development started last year and advances it into more robust, fit-for-purpose testing. As customer programs expand, manufacturers are requesting more advanced testing that better reflects real-world use and provides clearer decision-making data. Strengthening these capabilities will expand the Company’s service offerings, support regulatory readiness, and help customers demonstrate device safety and performance more effectively.
“This NRC IRAP support will help us to deepen our technical bench, problem solve for our customers and deliver solutions that reduce infections and complications for better health outcomes,” said Craig Milne, CEO. “It also positions us to meet rising client demand with higher-complexity testing and stronger technical support as standards and expectations continue to evolve.”
The funding is particularly timely as medical device manufacturers face increasingly stringent requirements from regulators such as the U.S. Food and Drug Administration and Health Canada. By enhancing its testing capabilities, Innovotech aims to help clients navigate these regulatory hurdles more efficiently. The company’s expertise in biofilm science and antimicrobial testing, including its proprietary MBEC Assay® platform, positions it to address the growing need for sophisticated testing that simulates real-world conditions.
For the medical device industry, the implications are significant. Improved testing methods can lead to better infection control, reduced complications, and ultimately improved patient outcomes. Manufacturers that leverage these advanced services may gain a competitive edge by bringing safer products to market faster. The funding also underscores the Canadian government’s commitment to supporting innovation in life sciences, particularly in areas that address critical healthcare challenges.
Innovotech operates through ISO‑certified and GMP‑accredited laboratories and serves clients across multiple sectors and geographies. More information about the company and its services can be found at https://www.innovotech.ca.
